Last reviewed · How we verify
NCT06911710: CAR-T
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Phase 1, PHASE2 trial testing CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） in Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) in 90 participants. Currently enrolling.
28 February 2026
Quick facts
| Lead sponsor | Tianjin Medical University General Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 9 November 2024 |
| Primary completion | 28 February 2026 |
| Estimated completion | 28 February 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） — full drug profile →
Conditions studied
- Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) — all drugs for Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) →
- AML (Acute Myelogenous Leukemia) — all drugs for AML (Acute Myelogenous Leukemia) →
- Myeloma Multiple — all drugs for Myeloma Multiple →
- B-ALL — all drugs for B-ALL →
Sponsor
Tianjin Medical University General Hospital
Who can join
18 and older, any sex, with Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) or AML (Acute Myelogenous Leukemia). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06911710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Tianjin Medical University General Hospital trials
Trials by the same sponsor.
- NCT06228781 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis · NA · not yet recruiting
- NCT07498595 — TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07498439 — TILs Therapy for Multiple Primary Early-Stage NSCLC · EARLY_PHASE1 · not yet recruiting
- NCT07018375 — The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Th · Phase 4 · not yet recruiting
- NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06911710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University General Hospital
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06911710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing